ANNOUNCEMENT 07 Sep 2020

On 07 September 2020, the EIB provided financing worth EUR 10 million (USD 12 million).

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

EIB, Project financing summary, 'Microfluidic Technology R&d (Idff)', 07 September 2020.
https://www.eib.org/en/projects/loans/all/20200419

EIB, Project summary, 'Microfluidic Technology R&d (Idff)', 07 September 2020.
https://www.eib.org/en/projects/pipelines/all/20200419

EIB, Financed projects list
https://www.eib.org/en/projects/pipelines/index.htm?q=&sortColumn=projectStatusDate&sortDir=desc&pageNumber=0&itemPerPage=25&pageable=true&language=EN&defaultLanguage=EN&yearFrom=2020&yearTo=2020&orCountries.region=true&orCountries=true&orSectors=true&orStatus=true

European Investment Bank. Press release. Poland: EIB lends up to EUR 10 million to Scope Fluidics to develop diagnostics equipment for infectious diseases.
https://www.eib.org//en/press/all/2020-235-poland-eib-lends-up-to-eur-10-million-to-scope-fluidics-to-develop-diagnostics-equipment-for-infectious-diseases

Inception date: 07 Sep 2020 | Removal date: open ended

State loan

On 07 September 2020, the European Investment Bank (EIB) and Scope Fluidics SA signed an agreement worth EUR 10 million (approx. USD 12 million) for the project Microfluidic Technology R&d (Idff) from Poland. The total cost of the project is estimated at EUR 20 million.

According to the project description issued by the EIB, The Promoter is a Polish med tech company developing innovative products in the field of diagnostics and health care with a focus on antibiotic resistance of bacteria and viral pathogens (including Covid-19)..

The objective of the project is defined as following: The proposed transaction will support research and development (R&D) investments required to bring products to the market addressing high unmet medical needs, in a growing patient population, preserving and cultivating highly skilled employment opportunities..

A state act in the GTA database is assessed solely in terms of the extent to which its implementation affects foreign commercial interests. On this metric, the investment support granted here is discriminatory.

AFFECTED SECTORS

 

AFFECTED PRODUCTS